We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Debuts New Safety Rule for Bioequivalence Trials
FDA Debuts New Safety Rule for Bioequivalence Trials
October 12, 2010
To reduce the overreporting of adverse events in drug trials — including bioavailability and bioequivalence trials for generics — the FDA has issued a final rule that clarifies when and what events sponsors should report.